Lupus & antiphospholipid syndrome
Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies: a systematic review and meta-analysis
Authors' conclusion
Cumulative analysis of data from real-world studies confirmed adverse pregnancy outcomes of women with anti-SSA/RO
Study context
- Population
- Pregnancies in women with anti-SSA/RO antibodies; PubMed, Cochrane, Embase and Web of Science records
- Participants
- 1,675 participants1,920 pregnancies
- Outcome
- Rates of maternal and infant outcomes of pregnancy with anti-SSA/RO
Methodological detailspooled incidence rates, subgroup analysis
- Pooled incidence rates
- Subgroup analysis
Pooled result
As reported in the abstract
- Maternal: termination of pregnancy
- 4%
- Maternal: spontaneous abortion
- 5%
- Maternal: preterm labor
- 26%
- Maternal: cesarean operation
- 50%
- Fetal: perinatal death
- 4%
- Fetal: intrauterine growth retardation
- 3%
- Fetal: endocardial fibroelastosis
- 6%
- Fetal: dilated cardiomyopathy
- 6%
- Fetal: congenital heart block
- 7%
- Fetal: congenital heart block recurrence
- 12%
- Fetal: cutaneous neonatal lupus erythematosus
- 19%
- Fetal: hepatobiliary disease
- 12%
- Fetal: hematological manifestations
- 16%
Further pooled results
Congenital heart block prevalence (subgroup analysis)
- Diagnostic method and study region found to affect heterogeneity to some extent
Original publication
Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies: a systematic review and meta-analysis. Pediatr Rheumatol Online J. Published 4 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →